MCID: LYM115
MIFTS: 63

Lymphoma, Non-Hodgkin

Categories: Genetic diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoma, Non-Hodgkin

MalaCards integrated aliases for Lymphoma, Non-Hodgkin:

Name: Lymphoma, Non-Hodgkin 54 24 13 38 69
Non-Hodgkin Lymphoma 38 12 24 29 14
Familial Non-Hodgkin Lymphoma 24 71
Nhl 24 71
Lymphoma, Non-Hodgkin, Somatic 54
Lymphoma, Follicular, Somatic 54
Lymphoma Non-Hodgkins 52

Classifications:



External Ids:

OMIM 54 605027
Disease Ontology 12 DOID:0060060
MedGen 40 C0024305
ICD10 33 C85.7

Summaries for Lymphoma, Non-Hodgkin

UniProtKB/Swiss-Prot : 71 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, also known as non-hodgkin lymphoma, is related to non-hodgkin lymphoma, during pregnancy and non-hodgkin lymphoma, childhood, and has symptoms including lymphoma An important gene associated with Lymphoma, Non-Hodgkin is CASP10 (Caspase 10), and among its related pathways/superpathways are IL-2 Pathway and Apoptosis Modulation and Signaling. The drugs Bexxar and Intron A have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 72 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

Description from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin

Diseases related to Lymphoma, Non-Hodgkin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 non-hodgkin lymphoma, during pregnancy 12.2
2 non-hodgkin lymphoma, childhood 12.1
3 lymphoma 11.7
4 mantle cell lymphoma 11.5
5 thrombocytopenia, anemia, and myelofibrosis 11.3 BCL10 BCL2 BCL6
6 pseudotyphus of california 11.2 BCL2 BCL6 MALT1
7 blake pouch cyst 11.2 BCL2 BCL6 CD5
8 cervical endometrioid adenocarcinoma 11.2 ALK BCL6 CD5
9 biotin-responsive multiple carboxylase deficiencies 11.2 BCL10 BCL6 MALT1
10 folliculotropic mycosis fungoides 11.2 BCL10 IRF4 MALT1
11 pylorus cancer 11.2 BCL10 BCL2 BCL6 MALT1
12 raynaud disease 11.2 CCND1 CD5 MALT1
13 chronic intestinal vascular insufficiency 11.2 ALK PAX5 PTPRC
14 macrocephaly, mental retardation, short stature, spastic paraplegia and cns malformations 11.2 ALK FAS NPM1
15 primary malignant melanoma of the cervix 11.2 BCL2 BCL6 PAX5
16 pediatric lymphoma 11.2 BCL6 CD5 PAX5
17 mixed extragonadal germ cell cancer 11.2 ALK BCL2 CCND1 NPM1
18 uterine ligament endometrioid adenocarcinoma 11.2 ALK CD5 MYC
19 congenital sucrase-isomaltase deficiency with starch intolerance 11.2 ALK IRF4 NPM1 PTPRC
20 degenerative myopia 11.2 CD19 CD5 PAX5
21 methylmalonic acidemia cb1a type 11.2 CASP10 FAS PRF1 PTPRC
22 syngnathia cleft palate 11.2 BCL6 CD5 MALT1 PAX5
23 bagatelle cassidy syndrome 11.2 CD19 CD5 MS4A1 MYC
24 childhood spinal cord tumor 11.2 BCL6 CD5 PTPRC
25 hepatic osteogenic sarcoma 11.2 CCND1 CD5 PAX5
26 hodgkin's lymphoma, lymphocytic-histiocytic predominance 11.2 ALK BCL6 NPM1 PAX5 PTPRC
27 orofaciodigital syndrome iv 11.2 CASP10 FAS PRF1 PTPRC
28 lysosomal storage disease 11.2 BCL2 CCND1
29 paraneoplastic polyneuropathy 11.2 BCL2 BCL6 PTPRC
30 seckel syndrome 10 11.2 BCL6 FAS MS4A1 MYC PAX5
31 plummer vinson syndrome 11.2 BCL6 MS4A1 PTPRC
32 aorta atresia 11.2 ALK NPM1 PAX5 PTPRC
33 polycystic ovary syndrome 11.2 ALK BCL6 MS4A1
34 villoglandular endometrial endometrioid adenocarcinoma 11.2 BCL6 CD19 CD5 MALT1 PAX5
35 primary malignant melanoma of the conjunctiva 11.2 BCL6 IRF4 MYC
36 gastric cancer, somatic 11.2 BCL2 CASP10 CCND1 MYC
37 megakaryocytic leukemia 11.1 BCL2 BCL6 CCND1 CD19 CD5 MYC
38 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 11.1 BCL2 BRAF MS4A1
39 estrogen-receptor positive breast cancer 11.1 ALK BCL6 CD5 MYC NPM1 PTPRC
40 duodenal ulcer 11.1 CD5 IRF4 MYC
41 penile disease 11.1 ALK BCL6 CD19 CD5 IRF4 PTPRC
42 cholesteatoma 11.1 NPM1 PAX5 PTPRC
43 angiomatous meningioma 11.1 CD19 MYC PTPRC
44 lymphoma, malt, somatic 11.1 BCL10 BCL2 BCL6 CCND1 CD5 IRF4
45 gingival recession 11.1 BCL10 BCL2 BCL6 CCND1 IRF4 MS4A1
46 cpt deficiency, hepatic, type ia 11.1 CCND1 CD19 IRF4 MYC PTPRC
47 gastric small cell carcinoma 11.1 BCL6 PTPRC
48 pneumonic plague 11.1 CCND1 CD5 MYC
49 malignant melanocytic peripheral nerve sheath tumor of mediastinum 11.1 BCL6 CD19 MYC
50 lymphoma, large-cell, immunoblastic 11.1 BCL6 MYC PTPRC

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin:



Diseases related to Lymphoma, Non-Hodgkin

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin

Clinical features from OMIM:

605027

Human phenotypes related to Lymphoma, Non-Hodgkin:

32
id Description HPO Frequency HPO Source Accession
1 lymphoma 32 HP:0002665

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 BCL10 BCL2 FAS MALT1 RAD54B RAD54L
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 BCL10 BCL2 BRAF CCND1 FAS MALT1

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.45 RAD54L BCL10 BCL2 BCL6 BRAF CCND1
2 cellular MP:0005384 10.39 PAX5 PRF1 PTPRC RAD54B RAD54L BCL10
3 immune system MP:0005387 10.39 RAD54L BCL10 BCL2 BCL6 BRAF CCND1
4 growth/size/body region MP:0005378 10.29 ALK BCL2 BCL6 BRAF CCND1 CD19
5 homeostasis/metabolism MP:0005376 10.26 ALK BCL2 BCL6 BRAF CCND1 CD19
6 mortality/aging MP:0010768 10.24 RAD54B RAD54L ALK BCL10 BCL2 BCL6
7 endocrine/exocrine gland MP:0005379 10.22 BCL6 BRAF CCND1 FAS MYC PRF1
8 integument MP:0010771 10.13 ALK BCL2 BRAF CCND1 CD19 CD5
9 neoplasm MP:0002006 10.1 ALK BCL2 BRAF CCND1 CD19 FAS
10 digestive/alimentary MP:0005381 10.08 MYC PTPRC BCL2 BRAF CCND1 CD19
11 nervous system MP:0003631 10.07 ALK BCL10 BCL2 BRAF CCND1 CD19
12 liver/biliary system MP:0005370 10.01 BCL6 BRAF CD19 FAS MYC NPM1
13 normal MP:0002873 9.85 CD19 CD5 FAS MYC PAX5 PRF1
14 pigmentation MP:0001186 9.35 ALK BCL2 BRAF FAS MYC
15 respiratory system MP:0005388 9.17 ALK BCL2 BCL6 BRAF CCND1 FAS

Drugs & Therapeutics for Lymphoma, Non-Hodgkin

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Mozobil 17 46 PLERIXAFOR Genzyme December 2008
4
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech November 1997
5
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
6
Zevalin 17 46 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
7
Zydelig 17 46 IDELALISIB Gilead July 2014

Drugs for Lymphoma, Non-Hodgkin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 717)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
9
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1 29767-20-2 34698
10
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
11
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
12
Vidarabine Approved Phase 4,Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
13
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
14
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
15
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
16
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
17
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
18
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
21
Thioguanine Approved Phase 4,Phase 3,Phase 1,Phase 2 154-42-7 2723601
22
Vindesine Approved Phase 4,Phase 3,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
23 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
24
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
25
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
26
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
27
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
28
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 153559-49-0 82146
29
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
30
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
31
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
32
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
33
Bleomycin Approved Phase 4,Phase 3,Phase 1,Phase 2 11056-06-7 5360373
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
35
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-75-2 4033
36
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3375-50-6 598
37
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
39
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1 170729-80-3 151165 6918365
40
Fosaprepitant Approved Phase 4,Phase 1 172673-20-0 219090
41
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2 137-58-6 3676
42
Nitric Oxide Approved Phase 4 10102-43-9 145068
43
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
44
Prilocaine Approved Phase 4 721-50-6 4906
45
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
46
Infliximab Approved Phase 4 170277-31-3
47
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
48
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
49
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
50
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542

Interventional clinical trials:

(show top 50) (show all 3345)

id Name Status NCT ID Phase Drugs
1 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4 Rituximab
2 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
3 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
4 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
5 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
6 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
7 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
8 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
9 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
10 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
11 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
12 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
13 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
14 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
15 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
16 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
17 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
18 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
19 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
21 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
22 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands Completed NCT00731536 Phase 4
23 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
24 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
25 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
26 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
27 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
28 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
29 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
30 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
31 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
32 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
33 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Recruiting NCT03229200 Phase 4 Ibrutinib
34 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4 Tenofovir
35 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
36 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
37 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
38 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
39 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
40 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
41 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
42 Treatment of Diffuse Large B Cell Lymphoma Recruiting NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
43 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
44 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
45 EDOCH Alternating With DHAP for New Diagnosed Younger MCL Recruiting NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
46 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
47 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
48 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Active, not recruiting NCT01909934 Phase 4 brentuximab vedotin
49 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4 temsirolimus;temsirolimus
50 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting NCT01833039 Phase 4 Ibrutinib

Search NIH Clinical Center for Lymphoma, Non-Hodgkin

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Non-Hodgkin

Genetic tests related to Lymphoma, Non-Hodgkin:

id Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 29
2 Lymphoma, Non-Hodgkin 24 PRF1
3 Familial Non-Hodgkin Lymphoma 24

Anatomical Context for Lymphoma, Non-Hodgkin

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin:

39
B Cells, T Cells, Bone, Bone Marrow, Skin, Nk Cells, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin

Articles related to Lymphoma, Non-Hodgkin:

id Title Authors Year
1
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. ( 25600050 )
2015
2
Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003. ( 18657412 )
2008

Variations for Lymphoma, Non-Hodgkin

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin:

71
id Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin:

6 (show all 50)
id Gene Variation Type Significance SNP ID Assembly Location
1 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh37 Chromosome 8, 95403868: 95403868
2 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh37 Chromosome 1, 46738430: 46738430
3 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh37 Chromosome 2, 202074111: 202074111
4 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh37 Chromosome 2, 202070652: 202070652
5 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh37 Chromosome 2, 202073912: 202073913
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 PRF1 NM_001083116.1(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh37 Chromosome 10, 72358355: 72358355
8 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
9 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
10 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
11 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
12 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
13 MYD88 NM_001172567.1(MYD88): c.818T> C (p.Leu273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
14 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
15 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
16 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
17 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
18 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
19 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh37 Chromosome 15, 66727455: 66727455
20 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
21 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
22 MYC NM_002467.4(MYC): c.218C> T (p.Thr73Ile) single nucleotide variant Likely pathogenic rs756091827 GRCh37 Chromosome 8, 128750681: 128750681
23 B2M NM_004048.2(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 GRCh37 Chromosome 15, 45003747: 45003747
24 B2M NM_004048.2(B2M): c.1A> G (p.Met1Val) single nucleotide variant Likely pathogenic rs1023835002 GRCh37 Chromosome 15, 45003745: 45003745
25 B2M NM_004048.2(B2M): c.1A> T (p.Met1Leu) single nucleotide variant Likely pathogenic rs1023835002 GRCh37 Chromosome 15, 45003745: 45003745
26 B2M NM_004048.2(B2M): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs1057519879 GRCh37 Chromosome 15, 45003746: 45003746
27 B2M NM_004048.2(B2M): c.2T> G (p.Met1Arg) single nucleotide variant Likely pathogenic rs1057519879 GRCh37 Chromosome 15, 45003746: 45003746
28 EZH2 NM_004456.4(EZH2): c.1922A> T (p.Glu641Val) single nucleotide variant Likely pathogenic rs1057519894 GRCh37 Chromosome 7, 148508742: 148508742
29 EZH2 NM_004456.4(EZH2): c.1922A> C (p.Glu641Ala) single nucleotide variant Likely pathogenic rs1057519894 GRCh37 Chromosome 7, 148508742: 148508742
30 MAP2K1 NM_002755.3(MAP2K1): c.170A> C (p.Lys57Thr) single nucleotide variant Likely pathogenic rs1057519909 GRCh37 Chromosome 15, 66727454: 66727454
31 MYC NM_002467.4(MYC): c.217A> C (p.Thr73Pro) single nucleotide variant Likely pathogenic rs750664148 GRCh37 Chromosome 8, 128750680: 128750680
32 MYC NM_002467.4(MYC): c.173C> T (p.Pro58Leu) single nucleotide variant Likely pathogenic rs1057519918 GRCh37 Chromosome 8, 128750636: 128750636
33 PIK3CA NM_006218.3(PIK3CA): c.1031T> G (p.Val344Gly) single nucleotide variant Likely pathogenic rs1057519941 GRCh37 Chromosome 3, 178921549: 178921549
34 PIK3CA NM_006218.3(PIK3CA): c.1030G> A (p.Val344Met) single nucleotide variant Likely pathogenic rs1057519942 GRCh37 Chromosome 3, 178921548: 178921548
35 PIK3CA NM_006218.3(PIK3CA): c.1031T> C (p.Val344Ala) single nucleotide variant Likely pathogenic rs1057519941 GRCh37 Chromosome 3, 178921549: 178921549
36 RHOA NM_001664.3(RHOA): c.13C> T (p.Arg5Trp) single nucleotide variant Likely pathogenic rs1057519952 GRCh37 Chromosome 3, 49413010: 49413010
37 RHOA NM_001664.3(RHOA): c.14G> A (p.Arg5Gln) single nucleotide variant Likely pathogenic rs1057519953 GRCh37 Chromosome 3, 49413009: 49413009
38 RHOA NM_001664.3(RHOA): c.14G> T (p.Arg5Leu) single nucleotide variant Likely pathogenic rs1057519953 GRCh37 Chromosome 3, 49413009: 49413009
39 RHOA NM_001664.3(RHOA): c.125A> G (p.Tyr42Cys) single nucleotide variant Likely pathogenic rs1057519954 GRCh37 Chromosome 3, 49412898: 49412898
40 RHOA NM_001664.3(RHOA): c.125A> C (p.Tyr42Ser) single nucleotide variant Likely pathogenic rs1057519954 GRCh37 Chromosome 3, 49412898: 49412898
41 RHOA NM_001664.3(RHOA): c.125A> T (p.Tyr42Phe) single nucleotide variant Likely pathogenic rs1057519954 GRCh37 Chromosome 3, 49412898: 49412898
42 TP53 NM_000546.5(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Likely pathogenic rs730882008 GRCh37 Chromosome 17, 7577093: 7577093
43 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
44 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
45 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
46 TP53 NM_001126118.1(TP53): c.497A> G (p.Tyr166Cys) single nucleotide variant Likely pathogenic rs1057520007 GRCh37 Chromosome 17, 7578235: 7578235
47 TP53 NM_001126117.1(TP53): c.218A> T (p.Tyr73Phe) single nucleotide variant Likely pathogenic rs1057520007 GRCh37 Chromosome 17, 7578235: 7578235
48 TP53 NM_001126118.1(TP53): c.497A> C (p.Tyr166Ser) single nucleotide variant Likely pathogenic rs1057520007 GRCh37 Chromosome 17, 7578235: 7578235
49 TP53 NM_001126113.2(TP53): c.613T> A (p.Tyr205Asn) single nucleotide variant Likely pathogenic rs1057520008 GRCh37 Chromosome 17, 7578236: 7578236
50 TP53 NM_000546.5(TP53): c.613T> C (p.Tyr205His) single nucleotide variant Likely pathogenic rs1057520008 GRCh37 Chromosome 17, 7578236: 7578236

Cosmic variations for Lymphoma, Non-Hodgkin:

9 (show all 17)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 7
2 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 7
3 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 7
4 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 7
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 7
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 7
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 7
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 7
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 7
10 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 7
11 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 7
12 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 7
13 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 7
14 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 7
15 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 7
16 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 7
17 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 7

Copy number variations for Lymphoma, Non-Hodgkin from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CEP1 Non-Hodgkin''s lymphomas

Expression for Lymphoma, Non-Hodgkin

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin.

Pathways for Lymphoma, Non-Hodgkin